Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about P2RY12: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
P2RY12 is a gene implicated in neurodegeneration research. Key relationships include: inhibits, activates, co discussed. Associated with AD, ALS, AMI. Connected to 208 entities in the SciDEX knowledge graph.
| Gene Symbol | P2RY12 |
| Full Name | Purinergic Receptor P2Y12 |
| Chromosome | 3q25.1-q25.2 |
| Protein Type | Gpcr |
| Target Class | Gpcr |
| Function | P2RY12 is a Gi/o protein-coupled receptor for ADP that plays a critical role in microglial surveillance and neuroimmune responses in the brain. |
| Mechanism of Action | P2Y12 receptor antagonists blocking ADP-mediated signaling |
| Druggability | Medium (0.55) |
| Clinical Stage | Approved |
| Pathways | PI3K, MAPK |
| UniProt ID | Q9H244 |
| NCBI Gene ID | 29128 |
| Ensembl ID | ENSG00000170017 |
| GeneCards | P2RY12 |
| Human Protein Atlas | P2RY12 |
| Associated Diseases | AD, ALS, AMI, ARM, Aging |
| Known Drugs/Compounds | statins, rapamycin |
| Interactions | APOA1, ULK1, ATG5, EIF4EBP1, LC3, MTOR |
| SciDEX Target | View Target Profile (8 clinical trials) |
| SciDEX Hypotheses | Microglial Purinergic Reprogramming Purinergic P2Y12 Inverse Agonist Therapy |
| KG Connections | 555 knowledge graph edges |
| Databases | GeneCardsHPASTRING |
Knowledge base pages for this entity
flowchart TD
P2RY12["P2RY12<br/>Microglial Receptor"]
TREM2["TREM2<br/>Microglial Activation"]
Neuroinflammation["Neuroinflammation<br/>Chronic Inflammation"]
ALS["ALS<br/>Motor Neuron Disease"]
Neurodegeneration["Neurodegeneration<br/>Neural Cell Death"]
MTOR["mTOR<br/>Growth Signaling"]
ULK1["ULK1<br/>Autophagy Initiator"]
ATG5["ATG5<br/>Autophagosome Formation"]
LC3["LC3<br/>Autophagosome Marker"]
SQSTM1["SQSTM1/p62<br/>Cargo Adapter"]
Autophagy["Autophagy<br/>Cellular Cleanup"]
APOA1["APOA1<br/>Cholesterol Transport"]
ABCG1["ABCG1<br/>Cholesterol Efflux"]
Foam_Cell["Foam Cell<br/>Formation"]
Lipid_Accumulation["Lipid Accumulation<br/>in Microglia"]
P2RY12 --|"expressed in"|--> TREM2
P2RY12 --|"biomarker for"|--> Neuroinflammation
P2RY12 --|"associated with"|--> ALS
P2RY12 --|"associated with"|--> Neurodegeneration
P2RY12 --|"inhibits"|--> MTOR
P2RY12 --|"inhibits"|--> ULK1
P2RY12 --|"inhibits"|--> ATG5
P2RY12 --|"activates"|--> LC3
P2RY12 --|"activates"|--> SQSTM1
ULK1 --|"initiates"|--> Autophagy
ATG5 --|"promotes"|--> Autophagy
P2RY12 --|"regulates"|--> Autophagy
P2RY12 --|"inhibits"|--> APOA1
P2RY12 --|"inhibits"|--> ABCG1
P2RY12 --|"promotes"|--> Foam_Cell
P2RY12 --|"promotes"|--> Lipid_Accumulation
style P2RY12 fill:#006494
style Autophagy fill:#1b5e20
style APOA1 fill:#1b5e20
style ABCG1 fill:#1b5e20
style Neuroinflammation fill:#ef5350
style ALS fill:#ef5350
style Neurodegeneration fill:#ef5350
style Foam_Cell fill:#ef5350
style Lipid_Accumulation fill:#ef5350
style TREM2 fill:#4a1a6b
style MTOR fill:#4a1a6b
style ULK1 fill:#4a1a6b
style ATG5 fill:#4a1a6b
style LC3 fill:#5d4400
style SQSTM1 fill:#5d4400| Target | Relation | Type | Str |
|---|---|---|---|
| ds-f2c28aed24a7 | provides_data_for | dataset | 1.00 |
| UPREGULATES | upregulates | entity | 0.95 |
| platelet aggregation | regulates | process | 0.95 |
| LC3 | inhibits | entity | 0.90 |
| SQSTM1 | inhibits | entity | 0.90 |
| purinergic signaling | involved_in | pathway | 0.90 |
| autophagy | inhibits | process | 0.90 |
| PI3K-AKT | activates | entity | 0.90 |
| Vsmc-Derived Foam Cell Formation | promotes | process | 0.90 |
| microglia | expressed_in | cell_type | 0.85 |
| microglia activation | regulates | process | 0.80 |
| VSMC-derived foam cell formation | promotes | process | 0.80 |
| clopidogrel resistance | contributes_to | phenotype | 0.80 |
| Cholesterol Efflux | inhibits | process | 0.80 |
| MTOR | activates | gene | 0.80 |
| Microglia | biomarker_for | cell_type | 0.80 |
| microglial_process_motility | regulates | phenotype | 0.80 |
| purinergic signaling | participates_in | pathway | 0.75 |
| SQSTM1 | modulates | gene | 0.75 |
| Als | associated_with | disease | 0.75 |
| DAM microglia | expressed_in | cell_type | 0.75 |
| APOE | inhibits | gene | 0.70 |
| autophagy | regulates | process | 0.70 |
| foam cell formation | regulates | process | 0.70 |
| lipid accumulation | activates | process | 0.70 |
| "middle temporal gyrus"_spiny_L3 | expressed_in | cell_type | 0.70 |
| "middle temporal gyrus"_aspiny_L3 | expressed_in | cell_type | 0.70 |
| "middle temporal gyrus"_spiny_L5 | expressed_in | cell_type | 0.70 |
| TAU | stabilizes | protein | 0.70 |
| TAU | regulates | protein | 0.70 |
| APOE | protects_against | gene | 0.70 |
| PYROPTOSIS | inhibits | phenotype | 0.70 |
| TAU | associated_with | gene | 0.65 |
| TREM2 | associated_with | gene | 0.65 |
| Ptsd | associated_with | disease | 0.65 |
| APOE | treats | gene | 0.65 |
| MTOR | causes | gene | 0.65 |
| TMEM119 | activates | gene | 0.65 |
| AUTOPHAGY PATHWAY | regulates | pathway | 0.65 |
| ABCA1 | treats | gene | 0.65 |
| TAU | phosphorylates | protein | 0.65 |
| AKT | inhibits | gene | 0.65 |
| AKT | promotes | gene | 0.65 |
| Neuroinflammation | biomarker_for | disease | 0.65 |
| Inflammation | biomarker_for | disease | 0.65 |
| Atherosclerosis | inhibits | disease | 0.65 |
| Als | inhibits | disease | 0.65 |
| Inflammation | associated_with | disease | 0.65 |
| Neuroinflammation | associated_with | disease | 0.65 |
| Als | activates | disease | 0.65 |
| Source | Relation | Type | Str |
|---|---|---|---|
| ds-f2c28aed24a7 | data_in | dataset | 1.00 |
| MICROGLIA | expressed_in | entity | 0.90 |
| h-5daecb6e | targets_gene | hypothesis | 0.90 |
| h-f99ce4ca | targets_gene | hypothesis | 0.90 |
| MACROPHAGE | expressed_in | entity | 0.85 |
| h-5daecb6e | targets | hypothesis | 0.80 |
| h-f99ce4ca | targets | hypothesis | 0.80 |
| P2RX7 | inhibits | gene | 0.70 |
| MICROGLIA | treats | cell_type | 0.70 |
| APOE | associated_with | gene | 0.65 |
| CX3CR1 | associated_with | gene | 0.65 |
| AUTOPHAGY | associated_with | gene | 0.65 |
| ALZHEIMER | associated_with | gene | 0.65 |
| MICROGLIA | associated_with | gene | 0.65 |
| ALS | activates | disease | 0.65 |
| ATP | interacts_with | gene | 0.65 |
| ALZHEIMER'S DISEASE | interacts_with | disease | 0.65 |
| APOE | co_mentioned_with | gene | 0.60 |
| TMEM119 | expressed_in | gene | 0.60 |
| ACTB | inhibits | gene | 0.60 |
| ADORA2B | activates | gene | 0.60 |
| ATG5 | inhibits | gene | 0.60 |
| PI3K | inhibits | gene | 0.60 |
| LOX | inhibits | gene | 0.60 |
| MTOR | inhibits | gene | 0.60 |
| AKT | inhibits | gene | 0.60 |
| SQSTM1 | activates | gene | 0.60 |
| EIF4EBP1 | inhibits | gene | 0.60 |
| P62 | inhibits | gene | 0.60 |
| APOA1 | inhibits | gene | 0.60 |
| ULK1 | inhibits | gene | 0.60 |
| ABCA1 | inhibits | gene | 0.60 |
| ABCG1 | inhibits | gene | 0.60 |
| APOE | inhibits | gene | 0.60 |
| P2RY1 | activates | gene | 0.60 |
| P2RX7 | activates | gene | 0.60 |
| P2RX4 | activates | gene | 0.60 |
| PANX1 | activates | gene | 0.60 |
| P2RX1 | activates | gene | 0.60 |
| CD38 | associated_with | gene | 0.60 |
| P2RX5 | activates | gene | 0.60 |
| ABCA1 | activates | gene | 0.60 |
| APOE | co_discussed | gene | 0.60 |
| AKT | co_discussed | gene | 0.60 |
| ATG5 | co_discussed | gene | 0.60 |
| MTOR | co_discussed | gene | 0.60 |
| ABCA1 | co_discussed | gene | 0.60 |
| CLN3 | biomarker_for | gene | 0.60 |
| CXCL10 | therapeutic_target | gene | 0.60 |
| C1QA | therapeutic_target | gene | 0.60 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Microglial Purinergic Reprogramming | 0.483 | neurodegeneration | 4R-tau strain-specific spreading pattern |
| Purinergic P2Y12 Inverse Agonist Therapy | 0.480 | neurodegeneration | Synaptic pruning by microglia in early A |
| TREM2-P2RY12 Balance Restoration Therapy | 0.366 | neurodegeneration | Neuroinflammation and microglial priming |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-07 | 0 hypotheses
neurodegeneration | 2026-04-07 | 0 hypotheses
neurodegeneration | 2026-04-04 | 14 hypotheses Top: 0.508
neurodegeneration | 2026-04-04 | 0 hypotheses
neurodegeneration | 2026-04-02 | 5 hypotheses Top: 0.519
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Beyond Activation: Characterizing Microglial Functional Phenotypes. [PMID:34571885] | Lier J, Streit WJ, Bechmann I | Cells | 2021 | 2 |
| The P2RY12 receptor promotes VSMC-derived foam cell formation by inhibiting auto [PMID:32160082] | Pi S, Mao L, Chen J, Shi H, Liu Y, Guo X | Autophagy | 2021 | 2 |
| Convergence between Microglia and Peripheral Macrophages Phenotype during Develo [PMID:31818979] | Grassivaro F, Menon R, Acquaviva M, Otto | J Neurosci | 2020 | 1 |
| Role of P2Y(12) Receptor in Thrombosis. [PMID:27628007] | Zhang Y, Zhang S, Ding Z | Adv Exp Med Biol | 2017 | 1 |
| P2 purinergic receptors in systemic lupus erythematosus: from experimental findi [PMID:41825304] | Renaudineau Y, Brooks W | Current opinion in immunology | 2026 | 0 |
| Constitutive expression of CX3CR1-BAC-Cre introduces minimal off-target effects [PMID:41924777] | Mroue-Ruiz FH, Desai B, Garvin MM, Shehu | Biochemical and biophysical re | 2026 | 0 |
| [Advantageous therapeutic pathways and mechanisms of Jianpi Huogu Formula in tre [PMID:41814722] | Li T, Zhang C, Jia Y, Chen WH, Lin N, Zh | Zhongguo Zhong yao za zhi = Zh | 2026 | 0 |
| Differences in mRNA expression of neuroinflammation-related genes in the tempora [PMID:41843422] | Tan THL, McLean C, Christie M, Sanfilipp | Epileptic disorders : internat | 2026 | 0 |
| Clopidogrel Administration Impairs Neurovascular Unit Recovery and Exacerbates A [PMID:41898413] | Paul M, Paul JW, Hinwood M, Hood RJ, Mar | International journal of molec | 2026 | 0 |
| The gain-of-function TREM2-T96K mutation increases risk for Alzheimer's disease [PMID:41109213] | Pilat DJ, Le H, Prokopenko D, Lin CJ, Ei | Neuron | 2026 | 0 |
| Role of TREM2 in neuroinflammation. [PMID:41213496] | Abdulkhaliq AA, Alasiri G, Almoghrabi Y, | Exp Neurol | 2026 | 0 |
| Targeting Itga8 Mitigates Neurogenic Bladder Fibrosis Driven by Trem2⁺ Macrophag [PMID:41355531] | Wang J, Wang S, Ren L, Liu X, Zhang L et | Adv Sci (Weinh) | 2026 | 0 |
| Hepatocyte Mettl3 Deficiency Drives Primary Sclerosing Cholangitis and Liver Fib [PMID:41431138] | Pan W, Yong Y, Li Y, Shi G, Zhang M et a | Adv Sci (Weinh) | 2026 | 0 |
| Synergistic potential of TREM2 agonists and exercise training in Alzheimer's dis [PMID:41494649] | Zhang J, St Pierre Schneider B, Muguerza | Am J Physiol Endocrinol Metab | 2026 | 0 |
| Sulfatide deficiency-induced astrogliosis and myelin lipid dyshomeostasis are in [PMID:41513633] | He S, Mittra N, Bao H, Bhattacharjee A, | Nat Commun | 2026 | 0 |
| Peripheral cancer attenuates amyloid pathology in Alzheimer's disease via cystat [PMID:41576952] | Li X, Tang X, Zeng J, Duan L, Hou Z et a | Cell | 2026 | 0 |
| TREM2 expression level is critical for microglial state, metabolic capacity and [PMID:41580393] | Feiten AF, Dahm K, Schlepckow K, van Len | Nat Commun | 2026 | 0 |
| TREM2 deficiency delays postnatal microglial maturation and synaptic pruning, le [PMID:41930604] | Yang HC, Deng YS, Zhang J, Zhang T, Song | J Alzheimers Dis | 2026 | 0 |
| TREM2 in neurodegeneration and diseases. [PMID:41792456] | ["Abdulkhaliq A", "Alasiri G", "Kim B", | Molecular psychiatry | 2026 | 0 |
| Alzheimer's Disease as a Disorder of Neuroimmune Dysregulation. [PMID:41745721] | Aranda-Abreu GE, Rojas-Durán F, Hernánde | Neurology international | 2026 | 0 |